Gabapentin in generalized seizures

Epilepsy Research

Volumn 25, Issue 3, 1996, Pages 191-197

  Chadwick, David ^a   Leiderman, Deborah B ^b   Sauermann, Wilhelm ^c   Alexander, Jeannine ^b   Garofalo, Elizabeth ^b  

^a WALTON HOSPITAL   (United Kingdom)

^b PFIZER INC   (United States)

^c DATAMAP GmbH   (Germany)

Author keywords

anticonvulsant; clinical trials; epilepsy; gabapentin; generalized seizures

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GRAND MAL SEIZURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THROMBOCYTOPENIA; VERTIGO;

ACETIC ACIDS; ADOLESCENT; ADULT; AMINES; ANALYSIS OF VARIANCE; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; EPILEPSY, GENERALIZED; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030296518     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(96)00020-4     Document Type: Article

References (9)

1. [1] Anhut, H., Ashman, P., Feuerstein, T.J., Sauermann, W., Saunders, M., Schmidt, B. and The International Gabapentin Study Group, Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study, Epilepsia, 35 (1994) 795-801.
2. [2] Commission on Classification and Terminology of the International League Against Epilepsy, Proposal for revised clinical and electroencephalographic classification of epileptic seizures, Epilepsia, 22 (1981) 489-501.
3. [3] Commission on Classification and Terminology of the International League Against Epilepsy, Proposal for classification of epilepsies and epileptic syndromes, Epilepsia, 26 (1985) 268-278.
4. [4] Commission on Classification and Terminology of the International League Against Epilepsy, Proposal for revised classification of epilepsies and epileptic syndromes, Epilepsia, 30 (1989) 389-399.
5. [5] Leiderman, D., Garofalo, E. and LaMoreaux, L., Gabapentin patients with absence seizures: two double-blind, placebo controlled studies, Epilepsia, 34, Suppl. 6 (1993) 45.
6. [6] Taylor, C.P., Mechanism of action of new anti-epileptic drugs. In: D. Chadwick (Ed.), New Trends in Epilepsy Management: the Role of Gabapentin, Int. Congr. and Symp. Ser. No. 198, Royal Society of Medicine Services, London, 1993, pp. 13-40.
7. [7] Taylor, C.P., Emerging perspectives on the mechanism of action of gabapentin, Neurology, 44, Suppl. 5 (1994) S10-S16.
8. [8] UK Gabapentin Study Group, Gabapentin in partial epilepsy, Lancet, 335 (1990) 1114-1117.
9. [9] US Gabapentin Study Group No. 5, Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study, Neurology, 43 (1993) 2292-2298.